In the United States, annual vaccination against seasonal influenza is recommended for all persons aged ≥6 months ([@R1]). During each influenza season since 2004--05, CDC has estimated the effectiveness of seasonal influenza vaccine to prevent laboratory-confirmed influenza associated with medically attended acute respiratory illness (ARI). This report uses data from 4,562 children and adults enrolled in the U.S. Influenza Vaccine Effectiveness Network (U.S. Flu VE Network) during November 2, 2017--February 3, 2018. During this period, overall adjusted vaccine effectiveness (VE) against influenza A and influenza B virus infection associated with medically attended ARI was 36% (95% confidence interval \[CI\] = 27%--44%). Most (69%) influenza infections were caused by A(H3N2) viruses. VE was estimated to be 25% (CI = 13% to 36%) against illness caused by influenza A(H3N2) virus, 67% (CI = 54%--76%) against A(H1N1)pdm09 viruses, and 42% (CI = 25%--56%) against influenza B viruses. These early VE estimates underscore the need for ongoing influenza prevention and treatment measures. CDC continues to recommend influenza vaccination because the vaccine can still prevent some infections with currently circulating influenza viruses, which are expected to continue circulating for several weeks. Even with current vaccine effectiveness estimates, vaccination will still prevent influenza illness, including thousands of hospitalizations and deaths. Persons aged ≥6 months who have not yet been vaccinated this season should be vaccinated.

Methods used by the U.S. Flu VE Network have been published previously ([@R2]). At five study sites,[\*](#FN1){ref-type="fn"} patients aged ≥6 months seeking outpatient medical care for an ARI with cough within 7 days of illness onset were enrolled. Study enrollment began after local surveillance identified increasing weekly influenza activity or one or more laboratory-confirmed cases of influenza per week for 2 consecutive weeks. Patients were eligible for enrollment if they 1) were aged ≥6 months on September 1, 2017, and thus were eligible for vaccination; 2) reported an ARI with cough with onset ≤7 days earlier; and 3) had not been treated with influenza antiviral medication (e.g., oseltamivir) during this illness. After obtaining informed consent from patients or from parents or guardians for their children, participants or their proxies were interviewed to collect demographic data, information on general and current health status and symptoms, and 2017--18 influenza vaccination status. Nasal and oropharyngeal swabs (or nasal swabs alone for children aged \<2 years) were collected to obtain respiratory specimens; nasal and oropharyngeal swabs were placed together in a single cryovial with viral transport medium. Specimens were tested at U.S. Flu VE Network laboratories using CDC's real-time reverse transcription polymerase--chain reaction (rRT-PCR) protocol for detection and identification of influenza viruses. Participants (including children aged \<9 years, who require 2 vaccine doses during their first vaccination season) were considered vaccinated if they received ≥1 dose of any seasonal influenza vaccine ≥14 days before illness onset, according to medical records and registries (at the Wisconsin site); medical records and self-report (at the Washington site); or self-report only (at the Michigan, Pennsylvania, and Texas sites). VE against all influenza virus types combined and against viruses by type/subtype was estimated as 100% x (1 - odds ratio).[^†^](#FN2){ref-type="fn"} Estimates were adjusted for study site, age group, sex, race/ethnicity, self-rated general health, number of days from illness onset to enrollment, and week of illness (3-week intervals) using logistic regression. Interim VE estimates for the 2017--18 season were based on patients enrolled through February 3, 2018.

Among the 4,562 children and adults with ARI enrolled at the five study sites from November 2, 2017, through February 3, 2018, a total of 1,712 (38%) tested positive for influenza virus by rRT-PCR, including 1,392 (81%) influenza A viruses and 323 (19%) influenza B viruses ([Table 1](#T1){ref-type="table"}). Among 1,340 subtyped influenza A viruses, 1,143 (85%) were A(H3N2) viruses and 208 (16%) were A(H1N1)pdm09 viruses. Most (98%) influenza B viruses belonged to the B/Yamagata lineage. The proportion of patients with influenza differed by study site, sex, age group, race/ethnicity, self-rated health status, and interval from illness onset to enrollment ([Table 1](#T1){ref-type="table"}). The percentage of patients who were vaccinated ranged from 45% to 59% among study sites and differed by sex, age group, race/ethnicity, and self-rated health status.

###### Selected characteristics for 4,562 enrolled outpatients with medically attended acute respiratory illness and cough, by influenza test result status and seasonal influenza vaccination status --- U.S. Influenza Vaccine Effectiveness Network, United States, November 2, 2017--February 3, 2018

  Characteristic                           Test result status   p-value^†^       Vaccination status\*   p-value^†^                    
  ---------------------------------------- -------------------- ---------------- ---------------------- ------------ ---------------- ---------
  **Overall**                              **1,712 (38)**       **2,850 (62)**   **---**                **4,562**    **2,259 (50)**   **---**
  **Study site**                                                                                                                      
  Michigan                                 264 (35)             491 (65)         \<0.001                755          422 (56)         \<0.001
  Pennsylvania                             330 (41)             480 (59)         810                    376 (46)                      
  Texas                                    572 (42)             806 (58)         1,378                  614 (45)                      
  Washington                               195 (27)             518 (73)         713                    420 (59)                      
  Wisconsin                                351 (39)             555 (61)         906                    427 (47)                      
  **Sex**                                                                                                                             
  Male                                     735 (39)             1,133 (61)       0.03                   1,868        865 (46)         \<0.001
  Female                                   977 (36)             1,717 (64)       2,694                  1,394 (52)                    
  **Age group (yrs)**                                                                                                                 
  6 mos--8                                 359 (33)             739 (67)         \<0.001                1,098        535 (49)         \<0.001
  9--17                                    288 (49)             300 (51)         588                    204 (35)                      
  18--49                                   561 (36)             989 (64)         1,550                  642 (41)                      
  50--64                                   288 (39)             454 (61)         742                    436 (59)                      
  ≥65                                      216 (37)             368 (63)         584                    442 (76)                      
  **Race/Ethnicity**^§^                                                                                                               
  White                                    1,169 (37)           2,020 (63)       0.004                  3,189        1,659 (52)       \<0.001
  Black                                    161 (43)             218 (58)         379                    150 (40)                      
  Other race                               144 (33)             287 (67)         431                    217 (50)                      
  Hispanic                                 231 (42)             317 (58)         548                    225 (41)                      
  **Self-rated health status**                                                                                                        
  Fair or poor                             75 (31)              168 (69)         \<0.001                243          135 (56)         \<0.001
  Good                                     377 (35)             695 (65)         1,072                  559 (52)                      
  Very good                                618 (36)             1,087 (64)       1,705                  875 (51)                      
  Excellent                                639 (42)             898 (58)         1,537                  687 (45)                      
  **Illness onset to enrollment (days)**                                                                                              
  \<3                                      856 (48)             940 (52)         \<0.001                1,796        866 (48)         0.23
  3--4                                     589 (35)             1,082 (65)       1,671                  829 (50)                      
  5--7                                     267 (24)             828 (76)         1,095                  564 (52)                      
  **Influenza test result**^¶^                                                                                                        
  Negative                                 ---                  2,850            ---                    2,850        1,518 (53)       ---
  Influenza B positive                     323                  ---              ---                    323          132 (41)         ---
  B/Yamagata                               260                  ---              ---                    260          112 (43)         ---
  B/Victoria                               5                    ---              ---                    5            2 (40)           ---
  B lineage pending                        58                   ---              ---                    58           18 (31)          ---
  Influenza A positive                     1,392                ---              ---                    1,392        610 (44)         ---
  A(H1N1)pdm09                             208                  ---              ---                    208          60 (29)          ---
  A(H3N2)                                  1,143                ---              ---                    1,143        530 (46)         ---
  A subtype pending                        52                   ---              ---                    52           23 (44)          ---

\* Defined as having received ≥1 dose of influenza vaccine ≥14 days before illness onset. A total of 102 participants who received the vaccine ≤13 days before illness onset were excluded from the study sample.

^†^ The chi-square statistic was used to assess differences between the numbers of persons with influenza-negative and influenza-positive test results, in the distribution of enrolled patient and illness characteristics, and in differences between groups in the percentage vaccinated.

^§^ Enrollees were categorized into one of four mutually exclusive racial/ethnic populations: white, black, other race, and Hispanic. Persons identifying as Hispanic might have been of any race. Persons identifying as white, black, or other race were non-Hispanic. Race/ethnicity data were missing for 15 enrollees.

^¶^ Fourteen patients had coinfection with influenza A and influenza B, making the sum 1,726, or 14 greater than the total number of influenza-positive patients.

Among ARI patient participants, 43% of those with influenza had received the 2017--18 seasonal influenza vaccine, compared with 53% of influenza-negative participants ([Table 2](#T2){ref-type="table"}). After adjusting for study site, age group, sex, race/ethnicity, self-rated general health, number of days from illness onset to enrollment, and week of illness onset (3-week intervals), VE against medically attended ARI caused by all influenza virus types combined was 36% (CI = 27%--44%). VE for all ages was 25% (CI = 13% to 36%) against medically attended ARI caused by A(H3N2) virus infection, 67% (CI = 54%--76%) against influenza A(H1N1)pdm09 virus infection, and 42% (CI = 25%--56%) against influenza B virus infection. VE point estimates against medically attended influenza for all virus types varied by age group; statistically significant protection against medically attended influenza was found among children aged 6 months through 8 years (VE = 59%; CI = 44%--69%) and adults aged 18--49 years (VE = 33%; CI = 16%--47%), whereas no statistically significant protection was observed in other age groups.

###### Number and percentage receiving 2017--18 seasonal influenza vaccine among 4,562 enrolled outpatients with medically attended acute respiratory illness and cough, by influenza test result status, age group, and vaccine effectiveness against all influenza A and B and against virus types A(H3N2), A(H1N1)pdm09 and B --- U.S. Influenza Vaccine Effectiveness Network, United States, November 2, 2017--February 3, 2018

  Influenza type/Age group     Test result status   Vaccine effectiveness\*                                                    
  ---------------------------- -------------------- ------------------------- ----------- ---------------- ------------------- ----------------------
  **Influenza A and B**                                                                                                        
  **Overall**                  **1,712**            **741 (43)**              **2,850**   **1,518 (53)**   **33 (24 to 41)**   **36 (27 to 44)^†^**
  **Age group (yrs)**                                                                                                          
  6 mos--8                     359                  127 (35)                  739         408 (55)         56 (42 to 66)       59 (44 to 69)^†^
  9--17                        288                  100 (35)                  300         104 (35)         0 (-41 to 29)       5 (-38 to 34)
  18--49                       561                  198 (35)                  989         444 (45)         33 (17 to 46)       33 (16 to 47)^†^
  50--64                       288                  159 (55)                  454         277 (61)         21 (-6 to 42)       17 (-15 to 40)
  ≥65                          216                  157 (73)                  368         285 (78)         23 (-14 to 47)      18 (-25 to 47)
  **Influenza A(H3N2)**                                                                                                        
  **Overall**                  **1,143**            **530 (46)**              **2,850**   **1,518 (53)**   **24 (13 to 34)**   **25 (13 to 36)^†^**
  **Age group (yrs)**                                                                                                          
  6 mos--8                     200                  79 (40)                   739         408 (55)         47 (27 to 61)       51 (29 to 66)^†^
  9--17                        203                  75 (37)                   300         104 (35)         -10 (-60 to 24)     -8 (-62 to 29)
  18--49                       395                  155 (39)                  989         444 (45)         21 (-1 to 37)       20 (-4 to 38)
  50--64                       198                  115 (58)                  454         277 (61)         11 (-24 to 37)      12 (-26 to 39)
  ≥65                          147                  106 (72)                  368         285 (78)         25 (-16 to 51)      17 (-35 to 49)
  **Influenza A(H1N1)pdm09**                                                                                                   
  **Overall**                  **208**              **60 (29)**               **2,850**   **1,518 (53)**   **64 (52 to 74)**   **67 (54 to 76)^†^**
  **Age group (yrs)**                                                                                                          
  \<18                         105                  22 (21)                   1,039       512 (49)         73 (56 to 83)       78 (63 to 87)^†^
  18--64                       84                   26 (31)                   1,443       721 (50)         55 (28 to 72)       51 (20 to 70)^†^
  ≥65                          19                   12 (63)                   368         285 (78)         50 (-31 to 81)      34 (-96 to 78)
  **Influenza B**                                                                                                              
  **Overall**                  **323**              **132 (41)**              **2,850**   **1,518 (53)**   **39 (23 to 52)**   **42 (25 to 56)^†^**
  **Age group (yrs)**                                                                                                          
  \<18                         127                  46 (36)                   1,039       512 (49)         42 (14 to 60)       36 (1 to 58)^†^
  18--64                       151                  53 (35)                   1,443       721 (50)         46 (23 to 62)       50 (28 to 66)^†^
  ≥65                          45                   33 (73)                   368         285 (78)         20 (-62 to 60)      25 (-62 to 66)

**Abbreviation:** CI = confidence interval.

\* Vaccine effectiveness was estimated as 100% x (1 - odds ratio \[ratio of odds of being vaccinated among outpatients with influenza-positive test results to the odds of being vaccinated among outpatients with influenza-negative test results\]); odds ratios were estimated using logistic regression.

^†^ Statistically significant at the p\<0.05 level.

As of February 3, 2018, a total of 257 influenza A(H3N2) viruses from U.S. Flu VE Network participants had been characterized by CDC; 240 (93%) belonged to either genetic group 3C.2a (226 viruses) or the related subgroup 3C.2a1 (14), whereas 17 (7%) belonged to group 3C.3a. Genetic group 3C.2a includes the A/Hong Kong/4801/2014 reference virus representing the A(H3N2) component of the 2017--18 Northern Hemisphere influenza vaccines ([@R3]).

Discussion
==========

Early and widespread influenza activity during the 2017--18 influenza season provided the opportunity to estimate interim VE against several circulating influenza viruses, including the predominant A(H3N2) virus. These interim estimates reflect ongoing challenges with the A(H3N2) vaccine component since the 2011--12 season. The interim estimate of 25% VE against A(H3N2) viruses this season indicates that vaccination provided some protection, in contrast to recently reported, nonsignificant interim estimates of 17% from Canada and 10% from Australia ([@R4],[@R5]) and is similar to final (32%) VE estimates in the United States against A(H3N2) viruses during 2016--17[^§^](#FN3){ref-type="fn"} ([@R6]). However, among children aged 6 months through 8 years, the interim estimates against any influenza and A(H3N2) virus infection were higher; the risk for A(H3N2) associated medically-attended influenza illness was reduced by more than half (59%) among vaccinated children. Also, with interim VE estimates of 67% and 42% against influenza A(H1N1)pdm09 and B viruses, respectively, vaccination provided substantial protection against circulating A(H1N1)pdm09 viruses, as well as moderate protection against influenza B viruses predominantly belonging to the B/Yamagata lineage, the second influenza type B component included in quadrivalent vaccines. CDC continues to recommend influenza vaccination while influenza viruses are circulating in the community; several more weeks of influenza activity are likely. Influenza vaccination has prevented thousands of hospitalizations during previous seasons when influenza A(H3N2) viruses were predominant, including during the 2014--15 season when interim VE estimates were similar to those reported here. Appropriate use of influenza antiviral medications for treatment of severely ill persons or persons at high risk for complications from influenza who develop influenza symptoms is important, especially among older adults, who currently have the highest hospitalization rates ([@R3]).

VE estimates against A(H3N2) viruses have been lower than estimates against A(H1N1)pdm09 and B viruses for several years ([@R7]). Although there is no definitive evidence for antigenic drift of viruses circulating this season compared with cell culture--propagated reference viruses representing the A(H3N2) vaccine component ([@R3]), challenges with antigenic characterization of recent A(H3N2) viruses, many of which could not be characterized using traditional hemagglutination inhibition assays, have required the use of additional virus neutralization assays to assess antigenic characteristics. Multiple factors might be contributing to the reported VE against A(H3N2) viruses this season. Immune responses to vaccination differ by age and previous infection or vaccination history and can affect vaccine protection; higher VE against A(H3N2) viruses among young children suggests that vaccination might provide better protection against circulating A(H3N2) viruses to this age group. Also, genetic changes in the vaccine virus hemagglutinin protein that arise during passage in eggs might result in a vaccine immune response that is less effective against circulating viruses ([@R8],[@R9]). Human serologic data indicate decreased inhibition of circulating cell culture--propagated A(H3N2) viruses compared with egg-propagated viruses among persons vaccinated with egg-based vaccines.[^¶^](#FN4){ref-type="fn"} Additional studies are needed to assess whether VE against circulating A(H3N2) viruses varies by vaccine type, including comparisons between egg-based and non--egg-based vaccines. CDC will continue to monitor VE through the remainder of the season and is investigating these factors. In addition, many efforts are under way to improve selection and development of candidate vaccine viruses that are optimal for vaccine production and provide protection against a majority of circulating viruses.

These interim VE estimates underscore the need for influenza antiviral treatment for any patient with suspected or confirmed influenza who is hospitalized, has severe or progressive illness, or is at high risk for complications from influenza, regardless of vaccination status or results of rapid, point-of-care influenza diagnostic tests.[\*\*](#FN5){ref-type="fn"} CDC recommends antiviral medications as an adjunct to vaccination, and their potential public health benefit is increased in the context of low VE. A CDC health update issued December 27, 2017, regarding treatment with antiviral medications is available at <https://emergency.cdc.gov/han/han00409.asp>. Clinicians should be aware that influenza activity is widespread, and influenza should be considered as a possible diagnosis in all patients with acute respiratory illness.

The findings in this report are subject to at least four limitations. First, vaccination status included self-report at four of five sites. End-of-season VE estimates based on updated documentation of vaccination status might differ from interim estimates. Second, information from medical records and immunization registries is needed to evaluate VE by vaccine type and for fully vaccinated versus partially vaccinated children, as well as to evaluate the effects of previous season vaccination and timing of vaccination; end-of-season analysis of VE by vaccine type and effects of partial or previous season vaccination is planned. Third, an observational study design has greater potential for confounding and bias relative to randomized clinical trials. However, the test-negative design is widely used in VE studies and has been used by the U.S. Flu VE Network to estimate VE for previous influenza seasons. Finally, small sample sizes in some age groups resulted in wide confidence intervals, and end-of-season VE estimates could change as additional patient data become available or if there is a change in circulating viruses late in the season. It is also important to note that the VE estimates in this report are limited to the prevention of outpatient medical visits rather than more severe illness outcomes, such as hospitalization or death; data from studies measuring VE against more severe outcomes will be available at a later date.

Annual monitoring of VE supports ongoing efforts to improve influenza vaccines. Although more effective vaccines are needed, vaccination prevents a substantial burden of influenza-related illness annually. During the 2014--15 season, when VE against medically attended illness caused by any influenza virus was less than 20%, vaccination was estimated to prevent 11,000--144,000 influenza-associated hospitalizations and 300--4,000 influenza-associated deaths (<https://www.cdc.gov/flu/about/disease/2014-15.htm>). Small increases in VE can substantially affect the number of hospitalizations prevented during a severe season ([@R10]). Although interim estimates suggest that vaccination has prevented some influenza-related illness this season, influenza vaccines with improved effectiveness are needed to substantially reduce the incidence of disease.

###### Summary

What is already known about this topic?
---------------------------------------

Effectiveness of seasonal influenza vaccine can vary by season and has generally been higher against influenza A(H1N1)pdm09 and B viruses than against A(H3N2) viruses.

What is added by this report?
-----------------------------

So far this season, influenza A(H3N2) viruses have predominated, but other influenza viruses are also circulating. Based on data from 4,562 children and adults with acute respiratory illness enrolled during November 2, 2017--February 3, 2018, at five study sites with outpatient medical facilities in the United States, the overall estimated effectiveness of the 2017--18 seasonal influenza vaccine for preventing medically attended, laboratory-confirmed influenza virus infection was 36%.

What are the implications for public health practice?
-----------------------------------------------------

CDC continues to monitor influenza vaccine effectiveness. Influenza vaccination is still recommended; vaccination reduces the risk for influenza illnesses and serious complications. Treatment with influenza antiviral medications, where appropriate, is especially important this season.
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The U.S. Flu VE Network sites and the dates enrollment began are as follows: Kaiser Permanente Washington (Seattle, Washington) (November 27, 2017); Marshfield Clinic Research Institute (Marshfield, Wisconsin) (December 26, 2017); University of Michigan School of Public Health (the School of Public Health partnered with the University of Michigan Health System, Ann Arbor, and the Henry Ford Health System, Detroit, Michigan) (December 4, 2017); University of Pittsburgh Schools of the Health Sciences (the Schools of the Health Sciences partnered with the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania) (November 29, 2017); and Baylor Scott & White Health, Texas A&M University Health Science Center College of Medicine (Temple, Texas) (November 2, 2017).

100% x (1 - odds ratio \[ratio of odds of being vaccinated among outpatients with influenza-positive test results to the odds of being vaccinated among outpatients with influenza-negative test results\]).

<https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-06/flu-03-ferdinands.pdf>.

<http://apps.who.int/iris/bitstream/10665/259275/1/WER9242.pdf?ua=1>.

A complete summary of guidance for antiviral use is available at <https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm>. Groups at high risk for influenza complications include the following: children aged \<2 years; adults aged ≥65 years; persons with chronic pulmonary conditions (including asthma); persons with cardiovascular disease (except hypertension alone); persons with renal, hepatic, or hematologic (including sickle cell) disease; persons with metabolic disorders (including diabetes mellitus); persons with neurologic and neurodevelopmental conditions (including disorders of the brain, spinal cord, peripheral nerves and muscles, such as cerebral palsy, epilepsy \[seizure disorders\], stroke, intellectual disability \[mental retardation\], moderate to severe developmental delay, muscular dystrophy, or spinal cord injury); persons with immunosuppression, including that caused by medications or by human immunodeficiency virus infection; women who are pregnant or ≤2 weeks postpartum; persons aged \<19 years who are receiving long-term aspirin therapy; American Indian/Alaska Natives; persons with morbid obesity (i.e., body-mass index ≥40); and residents of nursing homes and other chronic-care facilities.
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